Fusion Antibodies annual free cash flow
2022
2023
2024
2025
Fusion Antibodies Free Cash Flow (FCF) History (FAB)
Fusion Antibodies reported −£1.4M in free cash flow for fiscal 2025, an increase of £397,000 from the previous fiscal year, with a free cash flow margin of −69.92%.
View full Fusion Antibodies company overviewFusion Antibodies free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-03-31 | −£1.4M | £397,000 | — | −69.92% |
| 2024 | 2024-03-31 | −£1.8M | £97,000 | — | −155.90% |
| 2023 | 2023-03-31 | −£1.9M | −£1.3M | — | −64.39% |
| 2022 | 2022-03-31 | −£588,000 | — | — | −12.25% |
Fusion Antibodies free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Fusion Antibodies source filings ↗